Future Medicine Co (XKRX:341170) ROCE % : -641.85% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Future Medicine Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Future Medicine Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -641.85%.

Future Medicine Co ROCE % Historical Data

The historical data trend for Future Medicine Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Future Medicine Co ROCE % Chart

Future Medicine Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-155.15

-282.06

-641.85

Future Medicine Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
ROCE %	Get a 7-Day Free Trial					-	-	-155.15	-282.06	-641.85

Future Medicine Co ROCE % Calculation

Future Medicine Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-3811.506	/	( ( (6445.517 - 3829.456)	+	(2174.766 - 3603.16) )	/ 2 )
	=	-3811.506	/	( (2616.061	+	-1428.394)	/ 2 )
	=	-3811.506	/	593.8335
	=	-641.85 %

Future Medicine Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	-3811.506	/	( ( (6445.517 - 3829.456)	+	(2174.766 - 3603.16) )	/ 2 )
	=	-3811.506	/	( ( 2616.061	+	-1428.394 )	/ 2 )
	=	-3811.506	/	593.8335
	=	-641.85 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2024) EBIT data.

Future Medicine Co (XKRX:341170) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Future Medicine Co ROCE % Related Terms

Thank you for viewing the detailed overview of Future Medicine Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Future Medicine Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Future Medicine Co Ltd (XKRX:341170) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

54 changup-ro, 616, 2 Techno Valley Enterprise Growth Center, Gyeonggi-do, Siheung-dong, LH Pangyo-je, Seongnam-si, KOR, 13449

Website

http://www.futuremedicine.co.kr

Future Medicine Co Ltd is a drug development company. It engages in the development of new drug candidates for anti-inflammatory/anti-fibrosis of non-alcoholic hepatitis (NASH) drugs, oral glaucoma treatments, and chronic kidney disease treatments, as well as targeted and Immuno cancer drugs.

Future Medicine Co Headlines

No Headlines